Are you looking to connect with others in the ETCTN 10422 clinical trial using abemaciclib and olaparib?
That's exciting that you're starting a clinical trial this week! Clinical trials give access to newer treatment combinations that aren't yet widely available, and many members have found them to be valuable options.
While Show Full Answer
Are you looking to connect with others in the ETCTN 10422 clinical trial using abemaciclib and olaparib?
That's exciting that you're starting a clinical trial this week! Clinical trials give access to newer treatment combinations that aren't yet widely available, and many members have found them to be valuable options.
While the search results don't mention anyone specifically in your trial, MyOvarianCancerTeam members do discuss their experiences with clinical trials. One member shared how they researched trials by going to ClinicalTrials.gov and narrowing down options based on location and eligibility, eventually finding a trial that combined a treatment from their first remission with a newer medication class.
Olaparib is a PARP inhibitor that's already FDA-approved and used in ovarian cancer treatment, so you'll be receiving it alongside abemaciclib as part of this research combination.
To find others in your specific trial, you might want to post about it on MyOvarianCancerTeam where members actively share their treatment experiences. You could ask about both the trial number and the drug combination to see if anyone responds.
Best of luck as you begin this week!
November 16, 2025
Join
Your Privacy Choices
